GPT and coronary artery disorder: Several clinical trials with bulevirtide showed an excellent safety profile and a significant reduction of biomarkers such as HDV RNA in serum and liver and normalization of alanine aminotransferase (ALT) in patients with CHD (Blank et al., 2016; Bogomolov et al., 2016; Blank et al., 2018; Wedemeyer et al., 2019; European Medicines Agency, 2020; Wedemeyer et al., 2022a; Wedemeyer et al., 2022b).